MA54741A - Composés thiényl-aniline destinés au traitement d'affections de la peau - Google Patents
Composés thiényl-aniline destinés au traitement d'affections de la peauInfo
- Publication number
- MA54741A MA54741A MA054741A MA54741A MA54741A MA 54741 A MA54741 A MA 54741A MA 054741 A MA054741 A MA 054741A MA 54741 A MA54741 A MA 54741A MA 54741 A MA54741 A MA 54741A
- Authority
- MA
- Morocco
- Prior art keywords
- thienyl
- treatment
- skin conditions
- aniline compounds
- aniline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769832P | 2018-11-20 | 2018-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54741A true MA54741A (fr) | 2021-11-24 |
Family
ID=70773567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054741A MA54741A (fr) | 2018-11-20 | 2019-11-20 | Composés thiényl-aniline destinés au traitement d'affections de la peau |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12466818B2 (https=) |
| EP (1) | EP3911313A4 (https=) |
| JP (1) | JP7546297B2 (https=) |
| CN (2) | CN113498340A (https=) |
| AU (1) | AU2019384645B2 (https=) |
| CA (1) | CA3120352A1 (https=) |
| MA (1) | MA54741A (https=) |
| WO (1) | WO2020106305A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466818B2 (en) | 2018-11-20 | 2025-11-11 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| CN113473986B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病萘啶酮苯胺化合物 |
| AU2019383311B2 (en) | 2018-11-20 | 2024-12-05 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| MA55143A (fr) * | 2018-11-20 | 2021-09-29 | H Lee Moffitt Cancer Center & Res Institute Inc | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau |
| US11010862B1 (en) * | 2019-11-14 | 2021-05-18 | Advanced Micro Devices, Inc. | Reduced bandwidth tessellation factors |
| KR20240125577A (ko) | 2021-11-23 | 2024-08-19 | 엔플렉션 테라퓨틱스, 인코포레이티드 | 피롤로피리딘-아닐린 화합물의 제형 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271164A (en) | 1979-04-16 | 1981-06-02 | Warner-Lambert Company | 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives |
| GB9420168D0 (en) | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| CA2290509A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| NZ501276A (en) | 1997-07-01 | 2000-10-27 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders |
| JP2910748B2 (ja) | 1997-11-12 | 1999-06-23 | 日本電気株式会社 | 異質同軸部材の端面の球状加工装置及びその方法 |
| HUP0105092A3 (en) | 1999-01-13 | 2003-12-29 | Warner Lambert Co | 1-heterocycle substituted diarylamines and medicaments containing them |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20050202001A1 (en) | 2002-04-24 | 2005-09-15 | Han-Mo Koo | Enhancement of human epidermal melanogenesis |
| CA2492112A1 (en) | 2002-08-06 | 2004-02-19 | F. Hoffmann-La Roche Ag | 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| WO2006078287A2 (en) * | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Pde4b inhibitors and uses therefor |
| AU2005252110B2 (en) | 2004-06-11 | 2008-09-04 | Shionogi & Co., Ltd. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer |
| US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| MX2007004781A (es) | 2004-10-20 | 2007-05-11 | Applied Research Systems | Derivados de 3-arilamino piridina. |
| CN102206216B (zh) | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| HRP20110498T1 (hr) | 2005-10-07 | 2011-08-31 | Exelixis | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| US7772233B2 (en) | 2006-04-19 | 2010-08-10 | Merck Serono, S.A. | Arylamino N-heteroaryl compounds as MEK inhibitors |
| GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| CN101528231A (zh) * | 2006-08-16 | 2009-09-09 | 埃克塞利希斯股份有限公司 | 在癌症的治疗中使用pi3k和mek调控剂 |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| ES2376771T3 (es) | 2006-08-21 | 2012-03-16 | Genentech, Inc. | Compuestos aza-benzofuranilo y métodos de utilización |
| RU2463038C2 (ru) | 2006-10-17 | 2012-10-10 | Нуво Рисерч Инк. | Диклофенаковый гель |
| EP2089359A2 (en) | 2006-10-31 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| EP2099796B1 (en) | 2006-11-30 | 2011-06-01 | Genentech, Inc. | Aza-indolyl compounds and methods of use |
| CL2008001373A1 (es) | 2007-05-11 | 2008-11-21 | Bayer Schering Pharma Ag | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. |
| WO2008148034A1 (en) * | 2007-05-25 | 2008-12-04 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| NZ586575A (en) | 2007-12-21 | 2012-03-30 | Genentech Inc | Azaindolizines and methods of use |
| GB0801080D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| GB0801081D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| DE102010012594A1 (de) | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
| WO2012040636A2 (en) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
| MX341471B (es) | 2010-11-05 | 2016-08-22 | Hoffmann La Roche | Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central. |
| WO2012099968A1 (en) | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating skin cancer associated diseases |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| JP5931187B2 (ja) | 2011-06-17 | 2016-06-08 | シェンヤン・シノケム・アグロケミカルズ・アールアンドディー・カンパニーリミテッドＳｈｅｎｙａｎｇ Ｓｉｎｏｃｈｅｍ Ａｇｒｏｃｈｅｍｉｃａｌｓ Ｒ＆Ｄ Ｃｏ．， Ｌｔｄ． | 置換シアノアニリン化合物、その調製法及び使用 |
| WO2014179785A1 (en) | 2013-05-03 | 2014-11-06 | Inscent, Inc. | Improved honeybee repellents and uses thereof |
| US10835513B2 (en) | 2013-06-28 | 2020-11-17 | The Regents Of The University Of California | Methods and treatments for the learning and memory deficits associated with Noonan syndrome |
| US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| CN105384754B (zh) | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| EP3383912A4 (en) | 2015-11-30 | 2019-11-06 | Ignyta, Inc. | TOPICAL FORMULATIONS |
| EP3301094A1 (en) | 2016-09-30 | 2018-04-04 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| US11161845B2 (en) | 2017-05-19 | 2021-11-02 | Nflection Therapeutics, Inc. | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
| MX2019013562A (es) | 2017-05-19 | 2020-08-03 | Nflection Therapeutics Inc | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. |
| WO2019139970A1 (en) | 2018-01-09 | 2019-07-18 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
| EP3873528A4 (en) | 2018-10-29 | 2022-08-10 | The Johns Hopkins University | Rasopathy treatment |
| MA55143A (fr) | 2018-11-20 | 2021-09-29 | H Lee Moffitt Cancer Center & Res Institute Inc | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau |
| US12466818B2 (en) | 2018-11-20 | 2025-11-11 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| WO2020106304A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Topical formulations |
| CN113473986B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病萘啶酮苯胺化合物 |
| AU2019383311B2 (en) | 2018-11-20 | 2024-12-05 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| WO2020106307A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks |
| EP4216952A4 (en) | 2020-09-24 | 2024-11-20 | NFlection Therapeutics, Inc. | TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDS |
| JP2024503892A (ja) | 2021-01-21 | 2024-01-29 | エヌフレクション セラピューティクス インコーポレイテッド | ピロロピリジン－アニリン化合物の結晶形 |
| US20240228480A1 (en) | 2021-01-21 | 2024-07-11 | Nflection Therapeutics, Inc. | Processes for preparing pyrrolopyridine-aniline compounds |
-
2019
- 2019-11-20 US US17/294,779 patent/US12466818B2/en active Active
- 2019-11-20 WO PCT/US2019/000067 patent/WO2020106305A1/en not_active Ceased
- 2019-11-20 JP JP2021527910A patent/JP7546297B2/ja active Active
- 2019-11-20 CN CN201980089585.XA patent/CN113498340A/zh active Pending
- 2019-11-20 EP EP19887349.9A patent/EP3911313A4/en active Pending
- 2019-11-20 CA CA3120352A patent/CA3120352A1/en active Pending
- 2019-11-20 CN CN202311548396.9A patent/CN117551073A/zh active Pending
- 2019-11-20 AU AU2019384645A patent/AU2019384645B2/en active Active
- 2019-11-20 MA MA054741A patent/MA54741A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7546297B2 (ja) | 2024-09-06 |
| CN113498340A (zh) | 2021-10-12 |
| CN117551073A (zh) | 2024-02-13 |
| US12466818B2 (en) | 2025-11-11 |
| EP3911313A1 (en) | 2021-11-24 |
| WO2020106305A1 (en) | 2020-05-28 |
| US20220204486A1 (en) | 2022-06-30 |
| AU2019384645A1 (en) | 2021-06-10 |
| CA3120352A1 (en) | 2020-05-28 |
| EP3911313A4 (en) | 2022-10-12 |
| AU2019384645B2 (en) | 2025-08-21 |
| JP2022510586A (ja) | 2022-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| MA54741A (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
| EP3448389A4 (en) | CHINAZOLINE AND INDOIND DERIVATIVES FOR THE TREATMENT OF MEDICAL DISORDER | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| IL281809A (en) | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | |
| EP3704108A4 (en) | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF HEMATOLOGICAL DISORDERS | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| MA55144A (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau | |
| EP3784260A4 (en) | Compositions for the treatment of skin conditions | |
| EP3883553A4 (en) | ARYL ANILINE AND HETEROARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER | |
| EP3950686A4 (en) | N-HETEROAROMATIC AMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| MA53664A (fr) | Composés destinés au traitement de certaines leucémies | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3790563A4 (en) | Compositions for the treatment of skin conditions | |
| EP3664812A4 (en) | TOPICAL SKIN COMPOSITIONS FOR TREATMENT OF ERYTHEMA OR SKIN INFLAMMATION | |
| EP3883552A4 (en) | CYANOARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN DISEASES | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| EP3773632A4 (en) | METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMA | |
| MA53562A (fr) | Polythérapie destinée au traitement d'une maladie hépatique | |
| EP3593803A4 (en) | COMPOUNDS FOR TREATING DISEASES CAUSED BY OXALATE ACCUMULATION | |
| MA51738A (fr) | Composés pour le traitement de la douleur |